Eurand Announces Conference Call On Second Quarter 2008 Financial Results: Financial News

Eurand Announces Conference Call On Second Quarter 2008 Financial Results
Friday July 18, 2008 8:00 am ET

AMSTERDAM, The Netherlands, July 18, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (NasdaqGM:EURX - News), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, will host a conference call on Thursday, August 7, 2008 at 8:30 AM ET to discuss its second quarter 2008 financial results. The conference call will be hosted by Gearoid Faherty, Chief Executive Officer, and Mario Crovetto, Chief Financial Officer.

The conference call schedule is as follows:



 7:00 a.m. ET: Second quarter 2008 financial results will be released

 8:20 a.m. ET: To participate in the conference call:

               -- U.S. Participants dial 1-877-407-9039
               -- International Participants dial +1-201-689-8470

 8:30 a.m. ET: Conference call begins promptly

 Call Replay: A replay of the call will be available until September
 7, 2008.  The Account Number is: 3055, Conference ID Number: 291529.

               -- U.S. Participants dial 1-877-660-6853
               -- International Participants dial +1-201-612-7415

A live webcast of the call will also be available from the Investor Relations section of the corporate web site at http://www.eurand.com. Following the live webcast, the archived version of the call will be available at the same URL until September 7, 2008.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four partnered products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand completed two phase III clinical trials for EUR-1008 (Zentase), intended for the treatment of Exocrine Pancreatic Insufficiency and, as announced on June 18, 2008, received an approvable letter from the FDA for its NDA for this product. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-masking/fast-dissolving formulations and drug conjugation. Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at http://www.eurand.com.